Tenecteplase for Acute Ischemic Stroke
نویسندگان
چکیده

 Both included economic evaluation studies (1 from Iran and 1 Australia) found that tenecteplase was the dominant treatment strategy (i.e., lower costs higher benefit) compared with alteplase over a lifetime horizon.
منابع مشابه
dysphagia in acute ischemic stroke
Introduction: Swallowing dysfunction complicates acute strokes in 25-32% of cases and directly affects patientschr('39') prognosis and recovery. Dysphagia complicates the course of acute strokes through its potential of the development of chest infection, nutritional problems, and dehydration. Dysphagia is also an independent predictor of respiratory morbidity and mortality in acute stroke. In...
متن کاملThrombolysis for acute ischemic stroke by tenecteplase in the emergency department of a Moroccan hospital
INTRODUCTION Thrombolysis has radically changed the prognosis of acute ischemic stroke. Tenecteplase is a modified form of rt-PA with greater specificity for fibrin and a longer half-life. We report the experience of a Moroccan tertiary hospital in thrombolysis using Tenecteplase. METHODS We conducted an open prospective study of all patients who were treated with Tenecteplase for an acute is...
متن کاملO10: Thrombo-Inflammation in Acute Ischemic Stroke
Ischemic stroke has been classified as a merely thrombotic disease, so the main goal of its treatment is the recanalization of the occluded vasculature. However, despite fast restoration of blood circulation, progressive stroke still develops in many patients, which has led to the concept of reperfusion injury. The underlying mechanism is only partly known. Though, it is accepted now, tha...
متن کاملA randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
BACKGROUND Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9 mg per kilogram of body weight) or tenecteplase (0.1 mg per kilogram or 0.25 mg per kilogram) less ...
متن کاملA pilot dose-escalation safety study of tenecteplase in acute ischemic stroke.
BACKGROUND AND PURPOSE Recombinant tissue-type plasminogen activator (rtPA) is the only approved treatment in acute ischemic stroke. However, intracerebral hemorrhage (ICH) occurs in 6.4% of patients treated with rtPA and limits its use. Tenecteplase (TNK) is a modified form of rtPA, with longer half-life and greater fibrin specificity. Patients after myocardial infarction had fewer systemic he...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian journal of health technologies
سال: 2023
ISSN: ['2563-6596']
DOI: https://doi.org/10.51731/cjht.2023.569